|
市場調查報告書
新一代序列：1000個基因組合的科學性、商業性影響
Next-Generation Sequencing: Scientific and Commercial Implications of the $1000 Genome
|
新一代序列：1000個基因組合的科學性、商業性影響 是由出版商Insight Pharma Reports在2007年08月所出版的。
這份英文市場調查報告書包含88 pages 價格從美金1250起跳。
Abstract
A growing number of companies and academic groups are reporting impressive
progress in commercializing new sequencing platforms that offer orders of
magnitude of improved throughput and cost. The prospect of routine,
personalized genome sequencing is suddenly within reach, not to mention
spectacular advances in a host of related fields.
This new report from CHI Insight Pharma Reports describes and assesses these developing technologies and their applications:
- Pyrosequencing
- Sequencing by synthesis
- Supported oligonucleotide detection (SOLiD)
- Single-molecule sequencing
- Nanopore sequencing
- Optical trapping
Next-Generation Sequencing: Scientific and Commercial Implications of the
$1000 Genome also includes the results and analysis of a quantitative Web
survey of the views, practices, and plans of individuals at life science
organizations involved with gene sequencing.
The applications covered in this report include:
- Personal genomics
- The Cancer Genome Atlas
- Evolutionary genomics
- Environmental genomics
The report also describes the efforts and progress of the companies that have
become leaders in the next-generation sequencing race, including:
- Applied Biosystems
- GE Healthcare
- Helicos BioSciences
- Illumina/Solexa
- Reveo
- Roche/454 Life Sciences
- VisiGen Biotechnologies
Next-Generation Sequencing: Scientific and Commercial Implications of the
$1000 Genome is an essential tool for individuals involved in R&D or
commercialization of next-generation sequencing technologies.
Table of Contents
SECTION 1
A BRIEF HISTORY OF GENOME SEQUENCING TECHNOLOGY AND MILESTONES
- Dideoxy (Sanger) Sequencing
- Automated DNA Sequencing
- Genome Wars
- The $1,000 Genome
SECTION 2
BEYOND SANGER SEQUENCING: NEXT-GENERATION SEQUENCING TECHNOLOGIES
- Sequencing-by-Synthesis/Pyrosequencing
- Sequencing-by-Synthesis
- Illumina
- GE Healthcare
- Intelligent Bio-Systems
- SOLiD (Supported Oligonucleotide Detection)
- Storage
- Polony Sequencing
- Single-Molecule Sequencing
- VisiGen
- Pacific Biosciences
- Nanopore Sequencing
- Optical Trapping
- Nanoscale Sanger Sequencing
SECTION 3
APPLICATIONS OF NEXT-GENERATION SEQUENCING
- The $1,000 Genome/Personal Genomics
- The Cancer Genome Atlas
- Evolutionary Genomics
- Environmental Genomics
- Gene Regulation
SECTION 4
EXPERT INTERVIEWS WITH TECHNOLOGY INNOVATORS
- Tony Smith, PhD, Illumina
- Susan Hardin, PhD, VisiGen
- Jay Shendure, MD, PhD, University of Washington, Seattle
- Kevin McKernan, ABI
- Stanley N. Lapidus, Helicos
SECTION 5
NEXT-GENERATION COMPANIES
- Applied Biosystems
- GE Healthcare
- Helicos BioSciences
- Illumina/Solexa
- Intelligent Bio-Systems
- Pacific Biosciences
- Reveo
- Roche/454 Life Sciences
- VisiGen
SECTION 6
CHI INSIGHT PHARMA REPORTS- NEXT-GENERATION SEQUENCING SURVEY- FEBRUARY 2007
APPENDIX
- NHGRI RESEARCH GRANTS
- $1,000 Genome Grants (August 2005)
- $100,000 Genome Grants
References
Company Index with Web Addresses
Tables:
- Table 2.1. Next-Generation Sequencing Technologies
- Table 2.2. Features of Major Next-Generation Sequencing Platforms
Figures:
- Figure 2.1. SOLiD: 2 Base Pair Encoding Using 4 Dyes
- Figure 2.2. SOLiD: Example of Decoding
- Figure 2.3. Apparatus for Single-Molecule Analysis Using Zero-Mode
Waveguides
- Figure 6.1. Survey Respondents by Sector
- Figure 6.2. Primary Involvement in Next-Generation Sequencing
- Figure 6.3. Application of Next-Generation Sequencing
- Figure 6.4. Organisms Sequenced Using New Platform(s)
- Figure 6.5. Active Use of Next-Generation Sequencing Systems
- Figure 6.6. Most Promising Platform
- Figure 6.7. Chief Application of Next-Generation Sequencing
- Figure 6.8. Areas of Disease Research to Benefit from Next-Generation
Sequencing
- Figure 6.9. Chief Technical Concerns about Next-Generation Sequencing
- Figure 6.10. Assessment of Current Platform Costs
- Figure 6.11. Cost of Full Human Genome Sequencing by 2010
- Figure 6.12. Dominant Platform
- Figure 6.13. Future Role of Sanger (Capillary) Sequencing
- Figure 6.14. Opinions Concerning GINA
|
